Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 + Gemcitabine + Docetaxel in Sarcomas and SCLC
NCT03449901Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2018
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Pegargiminase in soft tissue sarcoma (STS), osteosarcoma (OS), Ewing sarcoma and 1 more (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Progression-free Survival. Started May 2018; status: completed.
02
Drugs
Pegargiminase
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)Ewing sarcomasmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03449901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449901.